Market Cap 347.57M
Revenue (ttm) 1.88B
Net Income (ttm) -534.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -28.49%
Debt to Equity Ratio 2.46
Volume 2,863,500
Avg Vol 2,947,642
Day's Range N/A - N/A
Shares Out 112.48M
Stochastic %K 6%
Beta 0.76
Analysts Strong Sell
Price Target $5.83

Company Profile

Evolent Health, Inc., through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company offers integrated value-based care platform for health plan administration and management. It also provides administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggreg...

Industry: Health Information Services
Sector: Healthcare
Phone: 571 389 6000
Address:
1812 N. Moore Street, Suite 1705, Arlington, United States
PeakedSeller
PeakedSeller Aug. 4 at 8:20 PM
$EVH This post tries to sound analytical but fails at basic accounting. 1. Broken Leverage Math: their post calculates "Net Leverage" as $700M / $125M = 5.6x. That is GROSS leverage. Net leverage subtracts cash on hand. EVH holds over $140M in cash. Subtracting that from their debt drops true net leverage drastically. Her core math is fundamentally wrong. 2. Risk Corridor Value: Corridors aren't just an "airbag." By structurally capping downside risk, EVH safely captures upside profit (shared savings) without exposing its balance sheet to catastrophic medical utilization spikes. The 93.3% Q1 MER was expected due to upfront reserves for new patient onboarding, not permanent unprofitability. 3. Valuation Reality: Even valuing them purely on EV/EBITDA, EVH is trading at a distressed, near-bankruptcy discount. When their new $200M+ expansion launches in Q3 to drive the back-half margin ramp, this multiple will violently re-rate. Don't let bad math shake your conviction.
0 · Reply
nUme22
nUme22 Aug. 4 at 5:13 PM
$EVH buy below 3, preferably around 2.60
0 · Reply
StellaLunaSun
StellaLunaSun Aug. 4 at 3:20 PM
$EVH A 0.2x P/S ratio reflects EVH's negative margins and leverage, not undervaluation. Wall Street prices companies on cash flows and Enterprice Value (EV), not just raw revenue. Leverage Reality: Even at $700M debt vs $125M adjusted EBITDA, the Net Leverage is 5.6x ($700M / $125M). In healthcare services, >4.0x is risky junk territory. High revenue cannot pay down debt without margin. Risk Corridor Delusion: You confuse loss mitigation with profit. Corridors are an airbag; they stop bleeding but generate no value. With a devastating 93.3% MER, core operations remain deeply unprofitable. Peer Failure: The 2.6x industry average includes asset-light, 20%+ high-margin software platforms. EVH operates with negative net margins. Comparing them purely on revenue is a classic value trap
1 · Reply
PatBtmn
PatBtmn Aug. 4 at 2:54 PM
$EVH what a fucking loser
0 · Reply
PeakedSeller
PeakedSeller Aug. 4 at 2:39 PM
$EVH okay this my last post… but it needs to be shown how undervalued they are… The market has completely lost its mind on valuation here. To put this capitulation into perspective, let's look at the Price-to-Sales (P/S) multiples compared to its peers: * EVH is currently trading at an absurdly low 0.2x Price-to-Sales ratio. * For comparison, the broader Healthcare Services industry average sits much higher, at roughly 2.6x to 3.0x. * In fact, almost half of all healthcare services companies in the US command a P/S ratio greater than 2.2x. We are talking about a company that has reaffirmed its guidance for $2.4B to $2.6B in full-year 2026 revenue. Yet, at these levels, the market is pricing EVH as if it is headed for immediate bankruptcy. When a stock is trading at a fraction of its sector's multiple—0.2x vs 2.6x—simply reiterating cash flow targets next week won't just cause a bounce; it will force a violent upward re-rating back toward its peers.
1 · Reply
PeakedSeller
PeakedSeller Aug. 4 at 2:38 PM
$EVH The market is blindly selling EVH over macro healthcare utilization fears, completely ignoring Evolent's actual contract mechanics. 1. The Oncology Buffer: TD Cowen has noted that Evolent’s oncology cost trend is actually running BELOW their conservative 12% internal forecast. 2. Revenue Dominance: Approximately 65% of Evolent's 2026 revenue is driven by highly protected oncology contracts. 3. Macro Insulation: Yes, hospital utilization is spiking, but EVH structurally capped their downside. The primary health plans hold the catastrophic tail-risk, not EVH. Expectations are on the floor. Simply reiterating their $110M-$140M full-year EBITDA guide next week will act as a massive upside catalyst. Don't get shaken out by sector contagion!
0 · Reply
PeakedSeller
PeakedSeller Aug. 4 at 2:34 PM
$EVH EVERYONE IGNORE STELLA LUNA. I have responded to every one of his posts showing his misinformation. Don’t believe his little plea that he is trying to help educate. You are welcome to see my posts for accurate information. I have followed this stock for years and actually understand their business and have worked with them directly in my career.
0 · Reply
PeakedSeller
PeakedSeller Aug. 4 at 2:33 PM
$EVH This post is full of fundamental financial errors and outdated info. 1. Valuation Confusion: EVH’s P/E is NOT 0.18. That is their Price-to-Sales (P/S) ratio. Confusing P/E with P/S shows a total lack of financial literacy. 2. The Apple Comparison: Comparing a beaten-down small-cap trading at 0.2x sales to Apple is absurd. Apple is priced for perfection; EVH is priced for bankruptcy. When expectations are this low, simply meeting targets triggers a massive upward re-rating. 3. Debt Myth (Again): The $1B debt claim is outdated. Following their asset divestiture, they paid down the senior credit facility and the long-term debt is currently in the $700M range. 4. The MER "Gap": You are ignoring their narrowed risk corridors. EVH structurally capped their downside exposure, which protects their cash flow from the exact spiraling medical costs you are fearmongering about. There is no debt covenant crisis coming. Stop spreading misinformation to scare retail.
0 · Reply
StellaLunaSun
StellaLunaSun Aug. 3 at 2:30 PM
$EVH i hope we see a squezze i really wish to but i am only rational and that's why i am saying it is going to be hard.
0 · Reply
BPler
BPler Aug. 3 at 2:19 PM
$EVH No need to debate, ER will be before market opens on Thursday. So only 3 trading days left to see. Imho the current analyst saw the decline in sector based on medicaid and came to a wrong conclusion. Two big partner just got set-uped. Highmark already gave a positive public reference , which was not noted with enough wait or at all in current PTs https://www.bizjournals.com/pittsburgh/news/2026/07/07/highmark-collaborating-value-based-cancer-care.html
0 · Reply
Latest News on EVH
Evolent Health downgraded to Sell from Buy at Citi

2026-07-23T09:05:09.000Z - 12 days ago

Evolent Health downgraded to Sell from Buy at Citi


Evolent Health price target raised to $7 from $6 at Canaccord

2026-07-21T10:56:25.000Z - 14 days ago

Evolent Health price target raised to $7 from $6 at Canaccord


Evolent Health downgraded to Hold from Buy at Truist

2026-06-30T09:25:31.000Z - 5 weeks ago

Evolent Health downgraded to Hold from Buy at Truist


Evolent Health price target raised to $5.50 from $4 at Citi

2026-05-15T10:52:20.000Z - 2 months ago

Evolent Health price target raised to $5.50 from $4 at Citi


Evolent Health price target raised to $6 from $5 at Canaccord

2026-05-12T11:20:59.000Z - 3 months ago

Evolent Health price target raised to $6 from $5 at Canaccord


Evolent Health reports Q1 adjusted EPS (2c), consensus (5c)

2026-05-07T15:15:00.000Z - 3 months ago

Evolent Health reports Q1 adjusted EPS (2c), consensus (5c)


Evolent Health Earnings Call Transcript: Q1 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Evolent Health Earnings Call Transcript: Q1 2026


Evolent Health Earnings release: Q1 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Evolent Health Earnings release: Q1 2026


Evolent Health Slides: Q1 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Evolent Health Slides: Q1 2026


Evolent Health Quarterly report: Q1 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Evolent Health Quarterly report: Q1 2026


Evolent Announces First Quarter 2026 Results

May 7, 2026, 7:00 AM EDT - 3 months ago

Evolent Announces First Quarter 2026 Results


Evolent Health Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 3 months ago

Evolent Health Proxy statement: Proxy filing


Evolent Health Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 3 months ago

Evolent Health Proxy statement: Proxy filing


Evolent Health appoints Archie Mayani as Chief Product Officer

2026-03-19T12:56:59.000Z - 4 months ago

Evolent Health appoints Archie Mayani as Chief Product Officer


Evolent to Participate in Upcoming Investor Conferences

Feb 26, 2026, 5:00 PM EST - 5 months ago

Evolent to Participate in Upcoming Investor Conferences


Evolent Health price target lowered to $5 from $10 at UBS

2026-02-26T13:16:53.000Z - 5 months ago

Evolent Health price target lowered to $5 from $10 at UBS


Evolent Health price target lowered to $4 from $6 at Citi

2026-02-26T11:37:03.000Z - 5 months ago

Evolent Health price target lowered to $4 from $6 at Citi


Evolent Health price target lowered to $6 from $10 at Truist

2026-02-25T18:25:33.000Z - 5 months ago

Evolent Health price target lowered to $6 from $10 at Truist


Evolent Health price target lowered to $8 from $10 at BTIG

2026-02-25T12:24:40.000Z - 5 months ago

Evolent Health price target lowered to $8 from $10 at BTIG


Evolent Health price target lowered to $4 from $9 at Canaccord

2026-02-25T11:57:07.000Z - 5 months ago

Evolent Health price target lowered to $4 from $9 at Canaccord


Evolent Health Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

Evolent Health Earnings Call Transcript: Q4 2025


Evolent Health Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

Evolent Health Annual report: Q4 2025


Evolent Health Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

Evolent Health Earnings release: Q4 2025


Evolent Health Slides: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

Evolent Health Slides: Q4 2025


Evolent Health reports Q4 adjusted EPS 8c vs. (2c) last year

2026-02-24T21:20:38.000Z - 5 months ago

Evolent Health reports Q4 adjusted EPS 8c vs. (2c) last year


Evolent Health sees FY26 revenue $2.4B-$2.6B, consensus $2.38B

2026-02-24T21:18:28.000Z - 5 months ago

Evolent Health sees FY26 revenue $2.4B-$2.6B, consensus $2.38B


Evolent Health price target lowered to $10 from $16 at BTIG

2026-02-02T12:15:14.000Z - 6 months ago

Evolent Health price target lowered to $10 from $16 at BTIG


Evolent Health Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

Evolent Health Earnings Call Transcript: Q3 2025


Evolent Health Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

Evolent Health Quarterly report: Q3 2025


Evolent Health Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

Evolent Health Earnings release: Q3 2025


Evolent Health Slides: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

Evolent Health Slides: Q3 2025


Evolent Announces Third Quarter 2025 Results

Nov 6, 2025, 4:10 PM EST - 9 months ago

Evolent Announces Third Quarter 2025 Results


Evolent Health Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

Evolent Health Earnings Call Transcript: Q2 2025


Evolent Health Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

Evolent Health Quarterly report: Q2 2025


Evolent Health Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

Evolent Health Earnings release: Q2 2025


Evolent Health Slides: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

Evolent Health Slides: Q2 2025


Evolent Announces Second Quarter 2025 Results

Aug 7, 2025, 4:10 PM EDT - 1 year ago

Evolent Announces Second Quarter 2025 Results


Evolent announces key appointments to leadership team

Jul 9, 2025, 8:00 AM EDT - 1 year ago

Evolent announces key appointments to leadership team


Evolent Health Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

Evolent Health Earnings Call Transcript: Q1 2025


Evolent Health Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

Evolent Health Quarterly report: Q1 2025


Evolent Health Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

Evolent Health Earnings release: Q1 2025


Evolent Health Slides: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

Evolent Health Slides: Q1 2025


Evolent Announces First Quarter 2025 Results

May 8, 2025, 4:10 PM EDT - 1 year ago

Evolent Announces First Quarter 2025 Results


Evolent Health Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Evolent Health Proxy statement: Proxy Filing


Evolent Health Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Evolent Health Proxy statement: Proxy Filing


Evolent Health Earnings Call Transcript: Q4 2024

Feb 20, 2025, 5:00 PM EST - 1 year ago

Evolent Health Earnings Call Transcript: Q4 2024


Evolent Health Annual report: Q4 2024

Feb 20, 2025, 5:00 PM EST - 1 year ago

Evolent Health Annual report: Q4 2024


Evolent Health Earnings release: Q4 2024

Feb 20, 2025, 5:00 PM EST - 1 year ago

Evolent Health Earnings release: Q4 2024


Evolent Health Slides: Q4 2024

Feb 20, 2025, 5:00 PM EST - 1 year ago

Evolent Health Slides: Q4 2024


Evolent Announces Fourth Quarter and Full Year 2024 Results

Feb 20, 2025, 4:10 PM EST - 1 year ago

Evolent Announces Fourth Quarter and Full Year 2024 Results


Evolent Health Announces Changes to Board of Directors

Feb 4, 2025, 7:00 AM EST - 1 year ago

Evolent Health Announces Changes to Board of Directors


Evolent Health Earnings Call Transcript: Q3 2024

Nov 7, 2024, 5:00 PM EST - 1 year ago

Evolent Health Earnings Call Transcript: Q3 2024


Evolent Health Quarterly report: Q3 2024

Nov 7, 2024, 5:00 PM EST - 1 year ago

Evolent Health Quarterly report: Q3 2024


Evolent Health Earnings release: Q3 2024

Nov 7, 2024, 5:00 PM EST - 1 year ago

Evolent Health Earnings release: Q3 2024


Evolent Health Slides: Q3 2024

Nov 7, 2024, 5:00 PM EST - 1 year ago

Evolent Health Slides: Q3 2024


Evolent Announces Third Quarter 2024 Results

Nov 7, 2024, 4:10 PM EST - 1 year ago

Evolent Announces Third Quarter 2024 Results


Evolent Health Inc (EVH) Stock Price Down 3.2% on Oct 2

Oct 2, 2024, 12:08 PM EDT - 1 year ago

Evolent Health Inc (EVH) Stock Price Down 3.2% on Oct 2


Evolent Health Earnings Call Transcript: Q2 2024

Aug 8, 2024, 5:00 PM EDT - 2 years ago

Evolent Health Earnings Call Transcript: Q2 2024


Evolent Health Quarterly report: Q2 2024

Aug 8, 2024, 5:00 PM EDT - 2 years ago

Evolent Health Quarterly report: Q2 2024


Evolent Health Earnings release: Q2 2024

Aug 8, 2024, 5:00 PM EDT - 2 years ago

Evolent Health Earnings release: Q2 2024


Evolent Health Slides: Q2 2024

Aug 8, 2024, 5:00 PM EDT - 2 years ago

Evolent Health Slides: Q2 2024


Evolent Announces Second Quarter 2024 Results

Aug 8, 2024, 4:10 PM EDT - 2 years ago

Evolent Announces Second Quarter 2024 Results


Evolent Health Earnings Call Transcript: Q1 2024

May 9, 2024, 5:00 PM EDT - 2 years ago

Evolent Health Earnings Call Transcript: Q1 2024


Evolent Health Quarterly report: Q1 2024

May 9, 2024, 5:00 PM EDT - 2 years ago

Evolent Health Quarterly report: Q1 2024


Evolent Health Earnings release: Q1 2024

May 9, 2024, 5:00 PM EDT - 2 years ago

Evolent Health Earnings release: Q1 2024


Evolent Health Slides: Q1 2024

May 9, 2024, 5:00 PM EDT - 2 years ago

Evolent Health Slides: Q1 2024


Evolent Announces First Quarter 2024 Results

May 9, 2024, 4:10 PM EDT - 2 years ago

Evolent Announces First Quarter 2024 Results


Evolent Health Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Evolent Health Proxy statement: Proxy Filing


Evolent Health Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Evolent Health Proxy statement: Proxy Filing


Evolent Health Earnings Call Transcript: Q4 2023

Feb 22, 2024, 5:00 PM EST - 2 years ago

Evolent Health Earnings Call Transcript: Q4 2023


Evolent Health Annual report: Q4 2023

Feb 22, 2024, 5:00 PM EST - 2 years ago

Evolent Health Annual report: Q4 2023


Evolent Health Earnings release: Q4 2023

Feb 22, 2024, 5:00 PM EST - 2 years ago

Evolent Health Earnings release: Q4 2023


Evolent Health Slides: Q4 2023

Feb 22, 2024, 5:00 PM EST - 2 years ago

Evolent Health Slides: Q4 2023


Evolent Announces Fourth Quarter and Full Year 2023 Results

Feb 22, 2024, 4:10 PM EST - 2 years ago

Evolent Announces Fourth Quarter and Full Year 2023 Results


Evolent Health Slides: FY 2024

Jan 9, 2024, 6:45 PM EST - 2 years ago

Evolent Health Slides: FY 2024


Evolent Health Earnings Call Transcript: Q3 2023

Nov 2, 2023, 5:00 PM EDT - 2 years ago

Evolent Health Earnings Call Transcript: Q3 2023


Evolent Health Quarterly report: Q3 2023

Nov 2, 2023, 5:00 PM EDT - 2 years ago

Evolent Health Quarterly report: Q3 2023


Evolent Health Earnings release: Q3 2023

Nov 2, 2023, 5:00 PM EDT - 2 years ago

Evolent Health Earnings release: Q3 2023


Evolent Health Slides: Q3 2023

Nov 2, 2023, 5:00 PM EDT - 2 years ago

Evolent Health Slides: Q3 2023


Evolent Announces Third Quarter 2023 Results

Nov 2, 2023, 4:10 PM EDT - 2 years ago

Evolent Announces Third Quarter 2023 Results


Evolent Health to Participate in Upcoming Conferences

Aug 8, 2023, 5:00 PM EDT - 3 years ago

Evolent Health to Participate in Upcoming Conferences


Evolent Health Earnings Call Transcript: Q2 2023

Aug 2, 2023, 5:00 PM EDT - 3 years ago

Evolent Health Earnings Call Transcript: Q2 2023


Evolent Health Quarterly report: Q2 2023

Aug 2, 2023, 5:00 PM EDT - 3 years ago

Evolent Health Quarterly report: Q2 2023


Evolent Health Earnings release: Q2 2023

Aug 2, 2023, 5:00 PM EDT - 3 years ago

Evolent Health Earnings release: Q2 2023


Evolent Health Slides: Q2 2023

Aug 2, 2023, 5:00 PM EDT - 3 years ago

Evolent Health Slides: Q2 2023


Evolent Announces Second Quarter 2023 Results

Aug 2, 2023, 4:10 PM EDT - 3 years ago

Evolent Announces Second Quarter 2023 Results


Evolent welcomes Toyin Ajayi to its Board of Directors

Jul 26, 2023, 4:42 PM EDT - 3 years ago

Evolent welcomes Toyin Ajayi to its Board of Directors


PeakedSeller
PeakedSeller Aug. 4 at 8:20 PM
$EVH This post tries to sound analytical but fails at basic accounting. 1. Broken Leverage Math: their post calculates "Net Leverage" as $700M / $125M = 5.6x. That is GROSS leverage. Net leverage subtracts cash on hand. EVH holds over $140M in cash. Subtracting that from their debt drops true net leverage drastically. Her core math is fundamentally wrong. 2. Risk Corridor Value: Corridors aren't just an "airbag." By structurally capping downside risk, EVH safely captures upside profit (shared savings) without exposing its balance sheet to catastrophic medical utilization spikes. The 93.3% Q1 MER was expected due to upfront reserves for new patient onboarding, not permanent unprofitability. 3. Valuation Reality: Even valuing them purely on EV/EBITDA, EVH is trading at a distressed, near-bankruptcy discount. When their new $200M+ expansion launches in Q3 to drive the back-half margin ramp, this multiple will violently re-rate. Don't let bad math shake your conviction.
0 · Reply
nUme22
nUme22 Aug. 4 at 5:13 PM
$EVH buy below 3, preferably around 2.60
0 · Reply
StellaLunaSun
StellaLunaSun Aug. 4 at 3:20 PM
$EVH A 0.2x P/S ratio reflects EVH's negative margins and leverage, not undervaluation. Wall Street prices companies on cash flows and Enterprice Value (EV), not just raw revenue. Leverage Reality: Even at $700M debt vs $125M adjusted EBITDA, the Net Leverage is 5.6x ($700M / $125M). In healthcare services, >4.0x is risky junk territory. High revenue cannot pay down debt without margin. Risk Corridor Delusion: You confuse loss mitigation with profit. Corridors are an airbag; they stop bleeding but generate no value. With a devastating 93.3% MER, core operations remain deeply unprofitable. Peer Failure: The 2.6x industry average includes asset-light, 20%+ high-margin software platforms. EVH operates with negative net margins. Comparing them purely on revenue is a classic value trap
1 · Reply
PatBtmn
PatBtmn Aug. 4 at 2:54 PM
$EVH what a fucking loser
0 · Reply
PeakedSeller
PeakedSeller Aug. 4 at 2:39 PM
$EVH okay this my last post… but it needs to be shown how undervalued they are… The market has completely lost its mind on valuation here. To put this capitulation into perspective, let's look at the Price-to-Sales (P/S) multiples compared to its peers: * EVH is currently trading at an absurdly low 0.2x Price-to-Sales ratio. * For comparison, the broader Healthcare Services industry average sits much higher, at roughly 2.6x to 3.0x. * In fact, almost half of all healthcare services companies in the US command a P/S ratio greater than 2.2x. We are talking about a company that has reaffirmed its guidance for $2.4B to $2.6B in full-year 2026 revenue. Yet, at these levels, the market is pricing EVH as if it is headed for immediate bankruptcy. When a stock is trading at a fraction of its sector's multiple—0.2x vs 2.6x—simply reiterating cash flow targets next week won't just cause a bounce; it will force a violent upward re-rating back toward its peers.
1 · Reply
PeakedSeller
PeakedSeller Aug. 4 at 2:38 PM
$EVH The market is blindly selling EVH over macro healthcare utilization fears, completely ignoring Evolent's actual contract mechanics. 1. The Oncology Buffer: TD Cowen has noted that Evolent’s oncology cost trend is actually running BELOW their conservative 12% internal forecast. 2. Revenue Dominance: Approximately 65% of Evolent's 2026 revenue is driven by highly protected oncology contracts. 3. Macro Insulation: Yes, hospital utilization is spiking, but EVH structurally capped their downside. The primary health plans hold the catastrophic tail-risk, not EVH. Expectations are on the floor. Simply reiterating their $110M-$140M full-year EBITDA guide next week will act as a massive upside catalyst. Don't get shaken out by sector contagion!
0 · Reply
PeakedSeller
PeakedSeller Aug. 4 at 2:34 PM
$EVH EVERYONE IGNORE STELLA LUNA. I have responded to every one of his posts showing his misinformation. Don’t believe his little plea that he is trying to help educate. You are welcome to see my posts for accurate information. I have followed this stock for years and actually understand their business and have worked with them directly in my career.
0 · Reply
PeakedSeller
PeakedSeller Aug. 4 at 2:33 PM
$EVH This post is full of fundamental financial errors and outdated info. 1. Valuation Confusion: EVH’s P/E is NOT 0.18. That is their Price-to-Sales (P/S) ratio. Confusing P/E with P/S shows a total lack of financial literacy. 2. The Apple Comparison: Comparing a beaten-down small-cap trading at 0.2x sales to Apple is absurd. Apple is priced for perfection; EVH is priced for bankruptcy. When expectations are this low, simply meeting targets triggers a massive upward re-rating. 3. Debt Myth (Again): The $1B debt claim is outdated. Following their asset divestiture, they paid down the senior credit facility and the long-term debt is currently in the $700M range. 4. The MER "Gap": You are ignoring their narrowed risk corridors. EVH structurally capped their downside exposure, which protects their cash flow from the exact spiraling medical costs you are fearmongering about. There is no debt covenant crisis coming. Stop spreading misinformation to scare retail.
0 · Reply
StellaLunaSun
StellaLunaSun Aug. 3 at 2:30 PM
$EVH i hope we see a squezze i really wish to but i am only rational and that's why i am saying it is going to be hard.
0 · Reply
BPler
BPler Aug. 3 at 2:19 PM
$EVH No need to debate, ER will be before market opens on Thursday. So only 3 trading days left to see. Imho the current analyst saw the decline in sector based on medicaid and came to a wrong conclusion. Two big partner just got set-uped. Highmark already gave a positive public reference , which was not noted with enough wait or at all in current PTs https://www.bizjournals.com/pittsburgh/news/2026/07/07/highmark-collaborating-value-based-cancer-care.html
0 · Reply
StellaLunaSun
StellaLunaSun Aug. 2 at 8:43 AM
$EVH And anyone who hasn’t been completely oblivious will have noticed that even companies which performed better in their earnings reports have been punished – take Apple, for example. At the moment, the market is in such a state of panic that even meeting targets is no longer enough to drive a share price up. Anyone who thinks they’re guaranteed to make money as a day trader on 6 August could be hugely mistaken. I very much hope that Evolent meets its targets, even if that will be difficult, but there is a high probability – that the share price will fall further for the time being. Yes, the P/E ratio is cheap at around 0.18, but that’s only the case if the company really does generate a full $2 billion in turnover this year. But you can’t turn a blind eye to the massive debt of 1 billion. If the EBITA isn’t achieved due to the MER, a gap will emerge between the debt and the revenue, and then Evolent will run into problems with loans and the banks.
1 · Reply
StellaLunaSun
StellaLunaSun Aug. 2 at 8:26 AM
$EVH I just want to make one thing clear here: I’m absolutely bullish. But I hate it when people on forums are fed false information, and that’s what’s happening here. Yes, BlackRock has held Evolent shares for years, but NO, there were NO insider purchases. It’s just silly if you don’t really understand the subject matter, which is the case for many people here. What actually happened from a legal perspective is this: in the middle of the year (often in June/July), US companies pay out their annual share-based bonuses to their managers. These are known as RSUs (Restricted Stock Units). In SEC filings, this technically appears as ‘allocation/acquisition of shares’. However, the insiders did not pay a single cent out of their own pockets for this – it was part of their salary. Worse still: if you read these Form 4 filings very carefully, you will often see that the managers sold a portion of these new shares straight away on the same day. Why? To pay the tax due on this bonus.
1 · Reply
JustBen47
JustBen47 Aug. 1 at 10:25 PM
$EVH Partners with health plans and providers to manage specialty care, a market with long-term growth potential as healthcare shifts toward value-based reimbursement..
0 · Reply
PeakedSeller
PeakedSeller Aug. 1 at 12:42 PM
$EVH is trading at a generational discount sub-$3. The market is entirely ignoring the smart money here. We have massive institutional backing, with BlackRock recently disclosing a 5.5% stake, alongside major recent insider acquisitions in July from the CEO and President. The stock is trading at a forward P/E near 10 with a market cap completely disconnected from its massive revenue base. The current price action is a pure liquidity-driven panic, not fundamental reality. Analysts still hold average price targets over $6—representing 100%+ upside from today's levels. Smart money is holding while retail is shaken out. Buy the fear.
0 · Reply
PeakedSeller
PeakedSeller Aug. 1 at 12:41 PM
$EVH $EVH bears fundamentally misunderstand the contract mechanics. They think Evolent holds the bag on unlimited medical inflation. FALSE. Management intentionally shifted their Performance Suite contracts to narrowed risk corridors. This structurally caps downside risk—if utilization violently spikes, the primary health plans absorb the catastrophic tail risk, not EVH. Furthermore, these contracts feature inflation-adjusted true-ups upon renewal, giving $EVH immense pricing power and expanding margins over time. As specialty care gets more expensive, Evolent’s AI cost-containment becomes a mandatory shield for MCOs. The business model is highly protected and primed for growth.
0 · Reply
PeakedSeller
PeakedSeller Aug. 1 at 12:41 PM
$EVH is setting up for a massive reversal heading into the Aug 6 earnings print. The bear thesis assumes liquidity issues, but they generated over $52M in free cash flow recently. Wall Street is currently pricing in an apocalyptic worst-case scenario. Management literally only needs to reiterate their $110M-$140M full-year EBITDA guidance to completely dismantle the current short thesis. If they clear Q2, hold the line on guidance, and pave the way for their 2027 outlook ($250M EBITDA / $100M FCF), a violent multi-bagger re-rating is coming. Revenue is stable and the cash-flow math remains rock solid. This sub-$3 entry is a massive pre-earnings gift.
0 · Reply
PeakedSeller
PeakedSeller Aug. 1 at 12:40 PM
$EVH ignore this person. They are spreading fear for their short position and frankly their posts are innacurate and targeted.
1 · Reply
HimHit
HimHit Jul. 31 at 6:37 PM
$EVH Ladies and Gentleman I’M IN like $LESL and $ENLV
0 · Reply
PatBtmn
PatBtmn Jul. 31 at 4:35 PM
$EVH fuck you
1 · Reply
StellaLunaSun
StellaLunaSun Jul. 31 at 3:55 PM
$EVH Gabelli Funds sharply reduced its Evolent Health stake by 91.7% in the first quarter, selling 3.13 million shares and retaining 284,300 shares valued at approximately $648,000
0 · Reply
StellaLunaSun
StellaLunaSun Jul. 31 at 2:33 PM
$EVH The 13F reporting requirement: Institutional investors in the US are not required to report their shareholdings in real time. They are legally obliged to do so only every three months (quarterly) on a retrospective basis (via so-called 13F filings with the SEC). They even have 45 days after the end of the quarter to do so. The current reality: When Citigroup issues a warning and funds dump their holdings onto the market on a large scale, this mass sell-off only appears in the next official quarterly report. The statistical quirk: The figure of ‘98 per cent professional trading’ that you now see on your screen is actually based on data from the previous quarter.
0 · Reply
BPler
BPler Jul. 31 at 9:03 AM
$EVH Institutional Confidence is actually going up with lower prices, so it in fact looks like people with deeper understanding for the market are buying in while mostly financial focused investors without market knowledge getting scared by financial instutions like Shiti Group $C Sources: https://www.tradingkey.com/markets/stocks/evh/sentiment https://fintel.io/so/us/evh
1 · Reply